FTO and neoplasm: However, recent studies have identified new and promising FTO inhibitors as shown in Table 2 [95–114], including FB23, FB23-2, CS1, and CS2, which have exhibited potent anti-tumor effects with minimal side effects in the treatment of acute myeloid leukemia (AML) [101, 107].